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Abstract
Introduction Screening for atrial fibrillation (AF) in people
≥65 years is now recommended by guidelines and expert
consensus. While AF is often asymptomatic, it is the
most common heart arrhythmia and is associated with
increased risk of stroke. Early identification and treatment
with oral anticoagulants can substantially reduce stroke
risk. The general practice setting is ideal for opportunistic
screening and provides a natural pathway for treatment
for those identified. This study aims to investigate the
feasibility of implementing screening for AF in rural general
practice using novel electronic tools. It will assess whether
screening will fit within an existing workflow to quickly
and accurately identify AF, and will potentially inform a
generalisable, scalable approach.
Methods and analysis Screening with a smartphone
ECG will be conducted by general practitioners and
practice nurses in rural general practices in New South
Wales, Australia for 3–4 months during 2018–2019. Up
to 10 practices will be recruited, and we aim to screen
2000 patients aged ≥65 years. Practices will be given
an electronic screening prompt and electronic decision
support to guide evidence-based treatment for those with
AF. De-identified data will be collected using a clinical
audit tool and qualitative interviews will be conducted
with selected practice staff. A process evaluation and
cost-effectiveness analysis will also be undertaken.
Outcomes include implementation success (proportion of
eligible patients screened, fidelity to protocol), proportion
of people screened identified with new AF and rates
of treatment with anticoagulants and antiplatelets at
baseline and completion. Results will be compared
against an earlier metropolitan study and a ‘control’
dataset of practices.
Ethics and dissemination Ethics approval was received
from the University of Sydney Human Research Ethics
Committee on 27 February 2018 (Project no.: 2017/1017).
Results will be disseminated through various forums,
including peer-reviewed publication and conference
presentations.
Trial registration number ACTRN12618000004268; Preresults.

Strengths and limitations of this study
►► New technology is used to quickly and efficiently

identify and treat atrial fibrillation (AF), within an existing workflow in the general practice setting.
►► General practices are ideally placed to screen for
and diagnose AF, as well to provide a pathway to
care for those identified during screening.
►► Conducting the study in the rural setting will inform
future AF screening policies to extend the evidence
base beyond metropolitan settings.
►► A potential limitation is the small size and non-randomised design, which would ideally be overcome in
a future large-scale study.

Introduction
Atrial fibrillation (AF) is the most common
heart arrhythmia, affecting 33.5 million
people worldwide.1 A person’s likelihood of
developing AF increases with age, reaching
37% for those aged ≥55 years.2 Importantly,
AF is associated with a fivefold increase in risk
of stroke.3 4 However, 1.4%–1.6% of the population aged ≥65 have undiagnosed AF,5 6 which
is commonly asymptomatic.7 8 Stroke caused
by AF is largely preventable with appropriate
oral anticoagulant (OAC) therapy, which
can reduce AF-related stroke risk by 64%.9
Although OAC is strongly recommended
by clinical practice guidelines for those with
additional stroke risk factors, as set out in the
CHA₂DS₂-VASc score,10 11 there has historically been a large gap between evidence and
practice with only 60% of eligible patients
prescribed OAC.12 Recently, there are signs
of improvement, with a recent Public Health
England report noting 77.9% of eligible
patients with AF in England were treated with
OAC.13 Similar increases in OAC prescription,
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largely due to the introduction of novel OACs, have been
reported in Spain and Denmark.14 15
Screening for AF in people ≥65 years by opportunistic
pulse palpation or ECG rhythm strip is now recommended by clinical practice guidelines and international
expert consensus.11 16 17 Many studies have demonstrated the effectiveness of opportunistic screening for
AF in general practice. The SAFE study demonstrated
that opportunistic screening of patients aged ≥65 years
by general practitioners (GPs), with a flag prompt on
the patient file, was an effective screening method.5 AF
screening in general practice was found to be promising
during influenza vaccination in the Netherlands,18 and
was successfully performed by practice nurses in the UK.19
Our previous research showed AF screening by practice
nurses to be feasible, both opportunistically and during
the influenza vaccination period.20 21
With 84% of Australian general practices employing
practice nurses,22 there is scope for AF screening to be
performed during existing practice nurse health appointments. Ideally, practice nurses could screen patients for
AF during the influenza or shingles vaccination and/or
coordinated chronic care consultations. These appointments are already funded by the Australian Government:
the influenza vaccination is recommended annually
and provided free for patients aged ≥65 years23; shingles vaccines will be provided free for people aged ≥70
with a 5-year catch-up programme for people aged
71–7924; annual health assessments are funded for those
aged ≥7525; and annual coordination consultations are
funded by Medicare for patients with chronic conditions
(eg, diabetes, cardiovascular) on a care plan.26 These are
all occasions when patients in the target age group are
likely to be available and receptive to AF screening, in an
appropriate setting.
While numerous studies have been conducted in
metropolitan areas, there is a paucity of data regarding
AF screening in rural areas. A recent systematic review of
AF screening studies conducted in rural settings acknowledged the need for more information on AF burden and
risk factors specifically in rural areas.27 In the Australian
context, it is known that people living in rural areas have
worse cardiovascular outcomes.28 It has been reported
that there is a lack of evidence about rural cardiovascular disease prevention and ‘characteristics associated
with quality of care’, which highlights the need for more
programmes in rural primary care, especially for highrisk patients.29 This study aims to implement a screening
programme with a quality improvement (QI) focus, to
better inform future AF screening policies to extend the
evidence base beyond metropolitan settings.
Methods and analysis
Design
This study, Atrial Fibrillation Screen, Management And
Guideline Recommended Therapy (AF-SMART II), will
investigate the feasibility of implementation of an AF
2

screening and use of an AF electronic decision support
tool (EDS), in rural general practices. It is a cross-sectional, observational implementation study of AF
screening using a smartphone ECG conducted by GPs
and practice nurses in up to 10 rural general practices
in New South Wales (NSW), Australia. It is very similar
to the study protocol used in the AF-SMART study which
was conducted in eight metropolitan general practices in
Sydney, Australia from 2016 to 2018. AF-SMART II is a
rural extension of AF-SMART with some important modifications based on feedback obtained in the metropolitan study. These modifications include: (1) an improved
electronic screening prompt to improve the proportion
of eligible patients screened; (2) the introduction of GP
continuing professional development (CPD)/QI points
to provide additional incentives for GPs; (3) a more structured approach to nurse screening and (4) a shorter
screening period.
Practice recruitment
A convenience sample of up to 10 rural general practices,
recruited through several NSW Primary Health Networks,
will be invited to participate in the study. Practices will be
required to:
►► Have at least one practice nurse.
►► Use either ‘Best Practice’ or ‘Medical Director’ as
the practice electronic patient record management
system.
►► Be willing to have ‘TopBar’ (PenCS third party software) and the clinical audit tool ‘PenCAT’ for data
collection installed (licences are provided by the
Primary Health Networks, NSW).
►► Have WiFi.
Preintervention: training and set up electronic study tools
Once a practice has been recruited, the preintervention
phase will involve setting up the electronic study tools
and relevant training. Each practice will be provided
with several Kardia smartphone ECG (iECG) devices to
screen for AF (figure 1). This device has approval from
the Australian Therapeutic Goods Administration as a
Medical Device, Class IIa and has a validated, automated
algorithm for detecting AF with 95% sensitivity and 99%
specificity.21
In addition, practices will be provided with two
custom-designed apps that were developed and tested in
the AF-SMART study (figures 2 and 3). These apps are
the:
1. AF app with screening prompt, which extracts data
from the electronic patient record and provides a
prompt for AF screening when an eligible patient’s file
is opened, and allows clinical staff to record the provisional screening results (figures 2 and 3).
2. EDS system, which guides evidence-based treatment
of those diagnosed with AF. The EDS is a clinically
validated QI tool, designed to bridge gaps between
evidence and practice in AF risk management.30 The
EDS extracts data from electronic patient records
Orchard JJ, et al. BMJ Open 2018;8:e023130. doi:10.1136/bmjopen-2018-023130
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for OAC, and recommendations against using aspirin
to treat AF.11 Practices will be provided with posters for
the reception area advertising the study and a laminated
participant information statement will be available at
reception.
Patient eligibility
All patients aged ≥65 years presenting to the general
practice for annual influenza vaccination, shingles vaccination, chronic care assessment or seeing their GP, will
be eligible for AF screening if they meet the following
criteria:
►► Age ≥65 years.
►► No current recorded diagnosis of AF.
►► Have not already been screened with the iECG in the
past 12 months.
Patients with terminal illness and patients unable to
provide informed consent will be excluded.

Figure 1

Kardia device and iECG reading.

regarding current OAC and antiplatelet prescriptions
and calculates individual stroke risk scores (CHA2DS2VASc) (figure 4). It then provides clinical staff with
evidence-based medication guidelines to support decisions on OAC prescription.
The apps are located in the TopBar hosting platform
that integrates with the general practice electronic patient
record management systems.
Once the technology set-up is complete, practice
nurses and GPs will receive training on the use of the
electronic tools and iECG as well as recent developments in evidence-based management of AF for stroke
prevention, highlighting guideline recommendations

Figure 2

Screening protocol
The screening intervention will be conducted for a period
of 3–4 months in each practice. The process is shown in
figure 5, and summarised below:
►► The AF screening prompt will notify clinical staff a
patient is eligible for iECG screening.
►► The GP/nurse will explain the screening process
and purpose, and obtain informed oral consent from
patients.
►► The GP/nurse will record a 30 s iECG. The iECG trace
will be visible in real time on the phone, and a pdf will
also be available to download from the secure Kardia
website. An automated interpretation (‘Possible AF’,
‘Normal’ or ‘Unclassified’) is provided immediately
after successful recording.
►► The GP/nurse will enter the iECG screening result
into the AF app in TopBar.
►► Depending on the iECG result, follow the appropriate
protocol.

Screenshot showing test patient file and TopBar apps. AF, atrial fibrillation.
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Figure 3

entering an iECG result in TopBar AF app (test patient shown). AF, atrial fibrillation; GP, general practitioner.

Protocol if a patient receives ‘possible AF’ diagnosis
The GP/nurse will inform the patient of the diagnosis
and give a brief explanation. If the nurse performed the
screening, the patient will be referred to their GP. Further
investigation and management is at the GP’s discretion,
which could include referral to a specialist. A 12-lead ECG
is recommended to provide additional confirmation for all

Figure 4

4

new AF diagnoses, and to add extra leads for AF diagnostic
workup. In some cases of paroxysmal AF, the 12-lead ECG
may show sinus rhythm while the iECG showed AF. This will
be obvious from a comparison of the p-waves on the lead I
iECG and lead I of the 12-lead ECG, as well as the regularity
of the rhythm. Following a 12-lead ECG, for patients with
confirmed AF, GPs will be encouraged to use the EDS to

Screenshot showing EDS recommendation for test patient. AF, atrial fibrillation; NOAC, novel oral anticoagulant.
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Figure 5

Process flow of AF screening. AF, atrial fibrillation; GP, general practitioner; OAC, oral anticoagulant.

review each patient’s CHA₂DS₂-VASc score and commence
guideline-recommended treatment to reduce stroke risk.
Protocol if a patient receives ‘normal’ diagnosis
The GP/nurse will inform the patient of the diagnosis.
No further action is required.
Orchard JJ, et al. BMJ Open 2018;8:e023130. doi:10.1136/bmjopen-2018-023130

Protocol if a patient receives ‘unclassified’ diagnosis
The GP/nurse will inform the patient of the diagnosis and
give a brief explanation based on information provided
by researchers. Depending on individual patient’s history
and iECG, a 12-lead ECG may be recommended by the
GP but follow-up is at the GP’s discretion. There are a
5
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number of conditions that can lead to this particular
diagnosis (eg, sinus tachycardia/bradycardia, left bundle
branch block, right bundle branch block or multiple
ectopic beats) which may or may not be clinically significant, or previously known.
CPD and QI points
In order to assist in practice recruitment, education and
training will be structured to be eligible for CPD points
for nurses and GPs. In addition, all practices will be
encouraged to use the research project to conduct an AF
QI programme that will attract specific QI professional
development points.
Study outcomes
Implementation success through process measures
including proportion of eligible patients seen in the
practice during the period who are screened (calculated from information available in the de-identified
data extracts), fidelity to the protocol and time taken
to complete the intervention.
►► Proportion of people screened identified with new AF.
►► Proportion of patients where EDS page accessed.
►► Proportion of eligible patients prescribed OAC as a
result of the intervention.
►► Proportion of patients with diagnosed AF prescribed
antiplatelet therapy during the study period.
►► Prevalence of AF at baseline (compared with metropolitan and control group, as defined below).
►► Incidence of new AF at completion of the intervention
(compared with metropolitan and control group).
►► Rates of treatment with anticoagulants and antiplatelets at baseline and at completion of the intervention
(compared with metropolitan and control group).
►► Acceptability, competing demands, barriers and
enablers according to staff involved in the intervention.
►► Cost-effectiveness analysis (ie, incremental cost-effectiveness ratio (ICER) of screening per quality-adjusted
life year (QALY) gained and per stroke avoided), using
data from Cadilhac et al31 to estimate the present value
of QALYs gained for each ischaemic stroke prevented.
►►

Data collection and sample size
The study aims to screen approximately 2000 patients in
total from up to 10 general practices. Assuming an incidence of 1.4% of people aged ≥65 with unknown AF,32 we
estimate 28 new cases of AF would be identified. A sample
size of 2000, assuming 1.4% incidence, would provide a
95% CI of 0.93% to 2.02% (18–40 cases).
PenCAT will be configured to collect de-identified
data from electronic patient records. These data include
demographic, medication and diagnostic information.
Data extracts will be taken at baseline, end of month
1, end of month 2 and end of month 3. The screening
period will be extended if required so that practices get
all four data extracts. Following each data extract, feedback will be provided to practices including a summary of
results (number screened by each staff member in total
and for that month).
6

Following completion of the iECG screening period,
selected staff from each practice will be interviewed to
gather their feedback as part of a comprehensive process
evaluation. Semistructured interviews with selected GPs,
practice nurses and practice managers will be carried out
by researchers at the end of the screening intervention.
The interviews will be audio recorded and transcribed.
Statistical analysis
Quantitative analysis
Descriptive analyses will be carried out both at the individual practice level and all practices pooled together.
Data collected in this study will be compared with data
collected from the earlier study in metropolitan Sydney,
and a database of ‘control’ practices with the same
data-parameters collected through concurrent studies
run by The George Institute. Analyses of these data will
be conducted using SAS v 9.4, with χ2 tests used to test
associations between AF incidence and method of detection (screen detected or clinically detected), and two-tail
p values<0.05 will be considered significant.
Cost-effectiveness analysis
A basic economic model for AF screening has previously
been developed and used in the SEARCH-AF33 study. This
model will be adapted and extended to evaluate screening
for AF by the practice nurse in the general practice. A
modelled cost-effectiveness analysis from an Australian
health funder perspective will be performed comparing
the cost of iECG population-based screening for AF, to
diagnosed AF in an unscreened population of Australian
men and women aged 65–84 years. Future costs will be
discounted at a rate of 5%. The results will be expressed
as an ICER per stroke avoided and per QALY gained.
Sensitivity analyses will be performed, including varying
the base assumptions of a guideline-adherence rate for
OAC prescription from 40% to 90% and increasing the
cost of treatment. We will obtain 95% CIs for all ICERs
using a multifactorial Monte Carlo simulation34 as
described in SEARCH-AF.33
Qualitative analysis
A detailed process evaluation using mixed methods will
be undertaken to evaluate the iECG screening process.
Realist evaluation35 will be used to analyse the interaction
of context, mechanisms for change and the outcomes
that are produced in both this study and the metropolitan
component. In this way, we will piece together a detailed
understanding of how the intervention influenced the
capacity, opportunity and motivation of providers to
improve detection and evidence-based treatment of AF.
Patient involvement
Development and refinement of the protocol was an
iterative process. Feedback obtained through interviews patients, nurses, GPs and practice managers about
their experience and preferences during previous AF
screening studies,20 21 contributed to the development of
the protocol. Following the study, participating practices
Orchard JJ, et al. BMJ Open 2018;8:e023130. doi:10.1136/bmjopen-2018-023130
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will be provided with a summary of the findings of the
study, together with a full copy of any publications, which
will be made available to patients in the practice reception area.
Ethics and dissemination
The study will comply with the National Health and
Medical Research Council ethical guidelines. Participating practices will provide written, informed consent
and patients being screened will provide oral consent. We
used the Standard Protocol Items: Recommendations for
Interventional Trials checklist when writing our protocol
report.36 The study will be administered by the Charles
Perkins Centre, University of Sydney. Results of the study
will be disseminated through various forums, including
peer-reviewed publications and presentation at national
and international conferences.
Conclusions
Screening for AF in people ≥65 years is now recommended by guidelines and international expert
consensus.11 16 Importantly, a comprehensive screening
programme should include a system to support evidencebased treatment for patients ultimately diagnosed with
the condition.16 General practices are well placed to
opportunistically screen older patients, and are ideal in
terms of the pathway for treatment for those identified.
This study will provide electronic prompts for screening
and test a patient-level EDS integrated with the practice’s
clinical software, to support evidence-based treatment.
In previous studies, a range of evidence-based interventions has been developed to increase effective prescribing
of guideline-recommended OAC in primary care settings.
These include use of EDS tools,37 targeted GP-education
programmes,38 consultant-led primary care anticoagulation assessment clinics39 and patient-focused education
interventions.40 Overall, these interventions increase
quality prescribing, but the results are varied in terms of
effect size and duration. One study with a large effect size
used a consultant-led anticoagulation assessment within
the general practice to identify and review patients with
AF with a CHA₂DS₂-VASc score ≥1 who were ‘suboptimally
anticoagulated’.39 This study reported a substantial and
significant increase in appropriate OAC treatment from
77% to 95% (p<0.0001), suggesting that an intensive,
systematic approach, together with numerous reminders
to improve patient attendance at in-person reviews, can be
very successful in increasing OAC uptake.39 In contrast, a
cluster-randomised study providing doctors with patientlevel recommendations via an EDS did not show significant improvements in evidence-based OAC treatment.37
This study aims to investigate the feasibility of implementing screening for AF in rural general practice. It
follows on from the first phase of the study conducted
in metropolitan general practice, allowing comparison
against a metropolitan setting and a control group of
Orchard JJ, et al. BMJ Open 2018;8:e023130. doi:10.1136/bmjopen-2018-023130

standard practices. The project will assess if screening
will efficiently fit within an existing workflow to quickly
and accurately identify AF. The study will also explore
the effect of GP and practice nurse education, electronic
screening prompts and EDS to facilitate evidence-based
treatment.
In Australia, the Heart Foundation’s Guideline for the
Diagnosis and Management of Atrial Fibrillation will be
released in August 2018, the draft guideline recommends
opportunistic screening for AF in general practice for
people aged ≥65 years. This study will potentially have
important implications for the implementation of a large
scale opportunistic AF screening programme for those
aged ≥65 years. It could also inform the design of a future
randomised trial of AF screening. It is anticipated that the
study will demonstrate that the general practice setting,
provided with additional electronic tools, can meet the
challenges of large-scale opportunistic screening with a
cheap, convenient, scalable solution.
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